Apellis Pharmaceuticals director sells over $1.45 million in company stock By Investing.com

Apellis Pharmaceuticals, Inc. (NASDAQ:) Director Dunlop A. Sinclair reported the sale of company stock valued at more than $1.45 million, according to a recent Form 4 filing with the Securities and Exchange Commission. The transactions, which took place on June 21, 2024, involved the sale of 36,000 shares at prices ranging from $39.22 to $39.63.

Specifically, Sinclair sold 35,305 shares at a weighted average price of $39.22 and an additional 1,695 shares at a weighted average price of $39.63. The sales were executed in multiple trades, with prices for the larger batch ranging from $38.59 to $39.58, while the smaller batch ranged from $39.59 to $39.67. After these transactions, Sinclair’s indirectly held ownership in the company stands at 136,998 shares.

The shares sold by Sinclair are indirectly owned through Epidarex Capital I LP, as indicated in the footnotes of the filing. While Sinclair, as a general partner of Epidarex, may be deemed to have voting and dispositive power over the shares held by Epidarex, he disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest.

Apellis Pharmaceuticals, based in Waltham, Massachusetts, operates in the pharmaceutical preparations industry. The company’s stock transactions are closely watched by investors, as insider sales and purchases can provide insights into the company’s financial health and future prospects.

In other recent news, Apellis Pharmaceuticals reported a successful first quarter in 2024 with a notable increase in net sales and continued progress in their clinical programs. The company’s flagship product SYFOVRE for geographic atrophy (GA) achieved net sales of $137.5 million, marking a 20% increase from the previous quarter. Additionally, Apellis secured a senior secured credit facility of up to $475 million with global investment firm Sixth Street, providing the company with increased flexibility and resources to invest in the launch of Syfovre and further the development of its wider drug pipeline.

However, Wells Fargo adjusted its outlook on Apellis, reducing the price target to $48 from the previous $57 due to competition concerns from Izervay. This adjustment reflects concerns over increased competition, especially following Izervay’s receipt of a J-code, which facilitates insurance billing and reimbursement. The firm suggests that Apellis’ stock price might stay within a certain range for the time being.

These are recent developments that also include Apellis settling its obligations with SFJ Pharma, effectively removing a development liability from its books. This move is expected to reduce its non-operating cash requirements by approximately $222 million through the end of 2027. According to Tim Sullivan, Apellis’ Chief Financial Officer, this deal positions the company to support its core operations without needing capital market funds.

InvestingPro Insights

As the investment community scrutinizes insider transactions for signals about a company’s confidence and direction, recent sales by Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Director Dunlop A. Sinclair have drawn attention. In light of these developments, a dive into the company’s financial health using InvestingPro’s real-time data and insights may offer additional context to investors.

InvestingPro data reveals a striking revenue growth for Apellis Pharmaceuticals, with a 394.93% increase over the last twelve months as of Q1 2024. Despite the impressive top-line expansion, the company’s profitability remains under pressure, as indicated by a negative P/E ratio of -11.07 for the same period. This aligns with the InvestingPro Tips, which suggest that analysts do not expect the company to be profitable this year. Furthermore, the company’s stock has experienced significant price volatility, with a one-week total return of -9.36% as of the reported date in 2024. Such metrics may influence insider selling decisions and investor sentiment alike.

On the balance sheet side, Apellis Pharmaceuticals operates with a moderate level of debt, and its liquid assets exceed short-term obligations, which may provide some reassurance regarding the company’s financial resilience. Notably, the company does not pay a dividend, which could be a factor for income-focused investors to consider.

For those seeking deeper insights, the InvestingPro platform offers additional tips for Apellis Pharmaceuticals, providing a comprehensive analysis that could be pivotal for making informed investment decisions. To access these valuable insights, visit https://www.investing.com/pro/APLS, and don’t forget to use the coupon code PRONEWS24 for an additional 10% off a yearly or biyearly Pro and Pro+ subscription. With a total of 8 InvestingPro Tips available, investors can delve further into the company’s financial nuances and market position.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.